ALKS
Alkermes plc.
$51.87
-0.07 (-0.13%)
At close · Jul 13
Market Cap
$8.65B
Shares
166,675,807
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.48B
-5.2%
FY2025
Net Income
$241.66M
-34.2%
FY2025
Gross Margin
86.69%
+2.4pp
FY2025
Operating Margin
17.21%
-9.8pp
FY2025
Diluted EPS
$1.43
-34.1%
FY2025
Operating Cash Flow
$520.75M
+18.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.73B – $1.84B | $1.56B | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B | $1.04B | $1.17B | $1.09B | $903.37M | $745.69M | $628.34M | $618.79M | $596.33M | $575.55M | $389.98M | |
| — | $208.84M | $196.46M | $245.33M | $253.04M | $218.07M | $197.32M | $178.32M | $180.39M | $176.42M | $154.75M | $132.12M | $138.99M | $175.83M | $170.47M | $170.47M | $127.58M | |
| — | $1.35B | $1.28B | $1.31B | $1.41B | $893.73M | $976.43M | $860.44M | $990.56M | $917.85M | $748.63M | $613.57M | $489.35M | $442.96M | $425.87M | $405.08M | $262.4M | |
| — | — | 86.69% | 84.25% | 84.79% | 80.39% | 83.19% | 82.83% | 84.59% | 83.88% | 82.87% | 82.28% | 77.88% | 71.58% | 71.41% | 70.38% | 67.29% | |
| — | $355.49M | $323.96M | $245.33M | $270.81M | $272.7M | $290.92M | $394.59M | $512.83M | $425.41M | $412.89M | $387.15M | $344.4M | $272.04M | $140.01M | $140.01M | $141.89M | |
| — | $512.64M | $480.01M | $446.21M | $490.15M | $392.21M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $281.77M | $221.51M | $199.02M | $199.6M | $198.54M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $794.41M | $701.52M | $645.24M | $689.75M | $590.75M | $549.61M | $538.83M | $599.45M | $526.41M | $421.58M | $374.13M | $311.56M | $199.91M | $125.76M | $125.76M | $137.63M | |
| — | — | — | $1.1M | $35.69M | $36.36M | $38.15M | $39.45M | $40.36M | $65.17M | $62.06M | $60.96M | $57.69M | $58.15M | $41.85M | $41.85M | $71.16M | |
| — | — | $27.17M | $28.53M | $74.93M | $77.86M | $78.65M | $81.85M | $80.41M | $103.66M | $98.52M | $94.26M | $85.6M | $98.09M | $73.75M | $73.75M | $93.68M | |
| — | — | — | — | $5.97M | — | — | $13.4M | $13.4M | — | — | — | — | $12.3M | $12.3M | $12.3M | — | |
| — | $1.37B | $1.22B | $1.14B | $1.25B | $1.12B | $1.08B | $1.15B | $1.35B | $1.19B | $1.05B | $954.36M | $852.64M | $705.93M | $561.86M | $493.74M | $478.26M | |
| — | $191.88M | $253.96M | $420.64M | $414.12M | -$6.09M | $97.75M | -$112.43M | -$175.48M | -$99.13M | -$147.9M | -$208.67M | -$224.3M | -$87.14M | $34.48M | $81.81M | -$88.28M | |
| — | — | 17.21% | 27% | 24.9% | -0.55% | 8.33% | -10.82% | -14.99% | -9.06% | -16.37% | -27.98% | -35.7% | -14.08% | 5.78% | 14.21% | -22.64% | |
| — | — | $281.12M | $449.17M | $489.05M | $71.77M | $176.4M | -$30.57M | -$95.07M | $4.53M | -$49.38M | -$114.41M | -$138.71M | $10.94M | $108.23M | $155.56M | $5.4M | |
| — | $33.17M | $12.28M | $22.58M | $23.03M | $13.04M | $11.22M | $8.66M | $13.6M | $15.44M | $12.01M | $14.89M | $13.25M | $13.43M | $48.99M | $48.99M | $28.11M | |
| — | $43.7M | $45.3M | $42.45M | $30.85M | $7.63M | $2.41M | $6.96M | $13.98M | $9.24M | $4.65M | $3.75M | $3.33M | $1.97M | $841K | $841K | $1.52M | |
| — | $12.15M | $37.49M | $23.11M | $7.4M | -$25.04M | -$10.02M | $15.89M | -$21.58M | -$27.84M | $4.63M | -$5.72M | $296K | $73.12M | -$21.22M | -$46.37M | -$26.11M | |
| — | $204.04M | $291.45M | $443.75M | $421.52M | -$31.13M | $87.73M | -$96.54M | -$197.06M | -$126.97M | -$143.27M | -$214.39M | -$224.01M | -$14.03M | $13.26M | $35.44M | -$114.39M | |
| — | $51.32M | $49.79M | $71.61M | -$97.64M | $2.02M | $11.33M | $14.32M | -$436K | $12.34M | $14.67M | -$5.94M | $3.16M | $16.03M | -$7.39M | $10.46M | -$714K | |
| — | $152.72M | $241.66M | $367.07M | $355.76M | -$158.27M | -$48.17M | -$110.86M | -$196.62M | -$139.31M | -$157.95M | -$208.44M | -$227.16M | -$30.06M | $24.98M | $24.98M | -$113.68M | |
| — | — | 16.37% | 23.57% | 21.39% | -14.24% | -4.1% | -10.67% | -16.79% | -12.73% | -17.48% | -27.95% | -36.15% | -4.86% | 4.19% | 4.34% | -29.15% | |
| — | — | — | — | — | — | — | — | — | -$139.31M | -$157.95M | -$208.44M | -$227.16M | -$30.06M | $20.65M | $24.98M | — | |
| — | $151.27M | $241.53M | $368.21M | $363.54M | -$165.43M | -$50.54M | -$110.39M | -$195.16M | -$138.8M | -$158.46M | -$207.92M | -$227.82M | -$43.77M | $25.18M | $25.18M | -$113.38M | |
| USD/shares | — | — | $1.47 | $2.22 | $2.14 | -$0.97 | -$0.30 | -$0.70 | — | — | — | — | -$1.52 | -$0.21 | $0.15 | $0.19 | -$0.99 |
| USD/shares | — | — | $1.43 | $2.17 | $2.10 | -$0.97 | -$0.29 | -$0.70 | — | — | — | — | -$1.52 | -$0.21 | $0.14 | $0.18 | -$0.99 |
| shares | — | — | 164.7M | 165.39M | 166.22M | 163.74M | 160.94M | 158.8M | 157.05M | 155.11M | 153.42M | 151.48M | 149.21M | 145.27M | 135.3M | 131.71M | 114.7M |
| shares | — | — | 168.74M | 169.2M | 169.73M | 163.74M | 164.75M | 158.8M | 157.05M | 155.11M | 153.42M | 151.48M | 149.21M | 145.27M | 144.01M | 137.1M | 114.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2024: $202.97M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.28×
Drug Manufacturers - Specialty & Generic median 2.09×
EV/EBIT
51.09×
Drug Manufacturers - Specialty & Generic median 34.62×
P/E (TTM)
57.63×
Drug Manufacturers - Specialty & Generic median 20.76×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $1,372,787,000 | $1,410,159,000 | $1,491,939,000 | $931,991,000 | $984,235,000 | $838,995,000 | $966,929,000 | $884,600,000 |
| Foreign Country Excluding Specified Country | $102,358,000 | $146,179,000 | $170,287,000 | $177,975,000 | $187,341,000 | $196,528,000 | $200,823,000 | $204,759,000 |
| Ireland | $754,000 | $1,294,000 | $1,179,000 | $1,829,000 | $2,175,000 | $3,233,000 | $3,195,000 | $4,915,000 |
| European Union | — | — | — | $750,000,000 | — | — | — | — |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Vivitrol | $467,912,000 | $457,315,000 | $400,419,000 | $379,478,000 | $343,853,000 | $310,722,000 | $335,365,000 | $302,609,000 |
| Aristada and Aristada Initio | $370,044,000 | $346,187,000 | $327,690,000 | $302,052,000 | $275,356,000 | $241,038,000 | $189,134,000 | $147,725,000 |
| LYBALVI | $346,687,000 | $280,032,000 | $191,889,000 | $96,022,000 | $8,215,000 | — | — | — |
| Royalty | $245,261,000 | $354,669,000 | $600,890,000 | $219,609,000 | $436,179,000 | $364,966,000 | $343,628,000 | $393,647,000 |
| Manufacturing Revenue | $45,995,000 | $119,426,000 | $142,498,000 | $112,374,000 | $105,628,000 | $119,034,000 | $104,254,000 | $133,028,000 |
| Aristada Or Aristada Initio | — | — | — | — | — | — | $189,134,000 | $147,725,000 |
| Manufactured Product and Royalty | — | $474,095,000 | $743,388,000 | $331,983,000 | $541,807,000 | $484,000,000 | $447,882,000 | $526,675,000 |
| Research and Development | — | $3,000 | $19,000 | $260,000 | $1,020,000 | $1,946,000 | $52,816,000 | $68,895,000 |
| License | — | — | — | $2,000,000 | $3,500,000 | $1,050,000 | $145,750,000 | $48,370,000 |
| Product | — | $1,083,534,000 | $919,998,000 | $777,552,000 | $627,424,000 | $551,760,000 | $524,499,000 | $450,334,000 |
Key facts
CIK
1520262
CUSIP
G01767105
13F (30d)
39 filings
20 filers
Visit website
Investor relations